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Investigating Genotype 1a HCV Drug Resistance in NS5A Region via
Bayesian Inference
Yao Fu, Gang Chen, Lizhi Fu, and Jing Zhang
Abstract: Hepatitis C virus (HCV) treatment is on the cutting edge of medicine. Due to the high rate of mutations and
low fidelity of HCV replication, resistant strains quickly become dominant in a viral population under the selection
pressure of a drug. In this paper, we examined the drug resistance mechanism in the NS5A region of genotype
1a HCV virus by comparing the sequence data from interferon-ribavirin treated and untreated patients. To find the
drug resistance difference, we used innovative Bayesian probability models to detect mutation combinations and
inferred detailed interaction structures of these mutations. We aim to provide reference to drug design and mutation
mechanism understanding through our work.
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Introduction

Hepatitis C virus (HCV) is a single-strand RNA virus
that was classified into at least six genotypes with
several subtypes in each genotype. Different genotypes
spread in different regions and have different response
patterns to interferon-based therapy[1] . Clinically,
interferon monotherapy treatment only leads to less
than 20% sustained response of chronic patients, while
IFN and ribavirin combined therapy has significantly
improved response rates[2, 3] . Understanding the
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mechanism of antiviral resistance to IFN therapy will
shed light on the design of better treatment strategies.
Variations, especially those in the NS5A region[4, 5]
in HCV sequences, have been found to play a
role in response to IFN-based therapies. NS5A is
a nonstructural protein that hampers the function of
dsRNA dependent protein kinase (PKR), an important
mediator of IFN response, leading to resistance of IFN
treatment[6, 7] . In 1995, Enomoto and Sato[8] defined
an “interferon sensitivity determining region” (ISDR
aa 2209–2248) in NS5A, implying that mutations in
this region was related to resistance to IFN. Several
studies have confirmed this finding[9–11] . Furthermore,
another study found that mutations in PKR binding
domain (PKRbd aa 2209–2274) of NS5A can block
viral replication[12] . However, contradictory results are
also obtained for these two regions, which makes the
role of NS5A to IFN ambiguous. In addition, other
domains in NS5A were also involved in HCV drug
resistance, such as variable region 3 (V3 aa 2356–
2379), a nuclear localization signal (NLS), AR1 (aa
2144–2185), AR2 (aa 2221–2272), and proline-rich
region (PRR aa 2283–2327)[13] .
This study will focus on NS5A region in HCV
genotype 1a. NS5A region has 1344 base pairs,
corresponding to 448 amino acids. The aim of this paper
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is to find possible amino acids that are correlated with
drug resistance.
Zhang et al.[14] proposed an innovative method
for investigating mutation interactions of HIV after
certain drug treatment. This method has been used
in detecting genome-wide associations on multiple
diseases[15–29] . In this paper, we applied a Bayesian
model equipped with Metropolis-Hastings algorithm
on the data of the interferon-based drug treatment to
select mutations associated with drug resistance. In
addition, the Recursive Model Selection (RMS)[14]
step is used to infer the dependence structure in the
interacting mutation positions found by the Bayesian
Variable Partition (BVP) model. This study confirms
the findings of several previous studies and uncovers
several interacting structures for these mutations.

2
2.1

Here, we first used the BVP model[14] to detect the
mutation positions. After that, we applied RMS to infer
the detailed dependence structure among the interacting
positions.
2.2

i . Suppose for every sequence in group A, we have p1
for the first value, p2 for the second value,    , pci for
ci
X
the last value, and
pj D 1. Then the likelihood for
j D1

group A’s data at position i is

Bayesian variable partition model

We will set up two data matrices A = [A1 ,    ,
Am ] (dimension nA  m) and B = [B1 ,    , Bm ]
(dimension nB  m ), where A and B denote the treated
and untreated group, respectively (each row is one
sequence, each column is one position of protein). Here
nA or nB denotes the number of sequences in treated or
untreated group and m denotes the number of positions
of protein. For the distribution of the positions of these
two groups, we propose the following four hypotheses:
 H1 hypothesis: The positions are independent of
each other and treated group and untreated group
have same probability distribution;
 H2 hypothesis: The positions are independent and
treated group and untreated group have different
probability distribution;
 H3 hypothesis: The positions are dependent and
treated group and untreated group have same
probability distribution;
 H4 hypothesis: The positions are dependent and
treated group and untreated group have different
probability distribution.
We are especially interested in positions in H2 and
H4. Given that position i is from H2 hypothesis, assume
that there are ci possible values (amino acid) at position

ci
Y

P .Ai jp1 ;    ; pci ; H2/ D

n

pj j ;

j D1

where nj denotes the number of sequences who take the
j -th value in Ai . For every sequence in B, we have p10
for the first value, p20 for the second value,    , pc0 i for
ci
X
the last value, and
pj0 D 1. Then the likelihood for
j D1

group B’s data at position i is
ci
Y

P .Bi jp10 ;    ; pc0 i ; H2/ D

0

.pj0 /nj ;

j D1
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nj0

where
denotes the number of individuals who take
the j -th value in Bi .
H2 means pj ¤ pj0 . However, we do not know these
pj and pj0 . So we assume they are random and use
Dirichlet prior on them.
p  Dirichlet.˛1 ;    ; ˛ci / W
ci
1 Y
˛
P .p1 ;    ; pci jH2; ˛1 ;    ; ˛ci / D
pj j
B.˛/

B.˛/ D

.˛j /

j D1

0

;

j D1

ci
Y

where

1

ci
X

@

1 ; ˛ D .˛1 ;    ; ˛ci /;
˛j A

j D1
1

Z
and

.x/ D

tx

1

e t dt:

0

p 0  Dirichlet.˛10 ;    ; ˛c0 i / W
P .p10 ;    ; pc0 i jH2; ˛10 ;    ; ˛c0 i / D
ci
Y

where

B.˛ 0 / D

;

.˛j0 /

ci
X

@

1 ; ˛ 0 D .˛10 ;    ; ˛c0 i /;
˛j0 A

j D1
1

Z
and

1

j D1

j D1

0

ci
0
1 Y
.pj0 /˛j
0
B.˛ /

.x/ D

tx

1

e t dt:

0

So
P .Ai ; p1 ;    ; pci jH2/ D
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ci
Y

n

pj j  Dirichlet.˛1 ;    ; ˛ci / D

j D1
ci
1 Y
n C˛
pj j j
B.˛/

1

I

j D1

P .Bi ; p10 ;   
ci
Y

j D1

; pc0 i jH2/ D

0

.pj0 /nj  Dirichlet.˛10 ;    ; ˛c0 i / D

j D1
ci
1 Y
0 nj0 C˛j0
/
.p
j
B.˛ 0 /

For H4 hypothesis, assume that there are c possible
value combinations of the dependent positions. Suppose
for every sequence in group A, we have p1 for the first
combination, p2 for the second combination,    , pc for
c
X
the last combination, and
pj D 1. For everyone in
group B, we havep10 for the first combination, p20 for the
second combination,    , pc0 for the last combination,
c
X
and
pj0 D 1. Then we can obtain:
j D1

1

:

P .dependent positions 0
in AjH4/1D

j D1

c
X

Integrating p and p 0 , respectively, we have:
Z
P .Ai jH2/ D P .Ai ; p1 ;    ; pci jH2/dp D

c
Y
j D1

p

j D1

.nj C ˛j /
.˛j /

ci
X

@
.nj C ˛j /
.˛j /

ci
X

.nj C ˛j /A

c
X

1;

c
Y

j D1

.nj0

C

where
A (B), and

p0

.nj0 C ˛j0 /

j D1

.˛j0 /

@
j D1

0

ci

X
@

c
X

P .dependent positions in A; BjH4/ D
P .dependent positions in A/  P .dependent positions in B/:

1
˛j0 A
1:

For H3 hypothesis, similarly, we have
P .dependent positions in 0
A; BjH3/1D

.nj0 C ˛j0 /A

c
X

c
Y

Then
P .Ai ; Bi jH2/ D P .Ai jH2/  P .Bi jH2/:
H1 means pj D pj0 . So for H1 hypothesis, similarly,
we have
Z
P .Ai ; Bi jH1/ D P .Ai ; Bi ; p1 ;    ; pci jH1/dp D
p

ci
Y
j D1

ci
nj Cnj0 C˛j 1
1 Y
pj
dp D
B.˛/
j D1
p
0
1
ci
X
@
˛j A
.nj C nj0 C ˛j /
j D1
0
1:
ci
.˛j /
X
@
.nj C nj0 C ˛j /A
j D1

.nj0 C ˛j0 /A

is the number of the j -th combination in

j D1

Z

1;

j D1

nj .nj0 /

P .Bi ; p10 ;    ; pc0 i jH2/dp 0 D

ci
Y

˛j0 A

j D1

0
@

P .Bi jH2/ D

ci
X

@

˛j0 /

.˛j0 /

j D1

0

1;

P .dependent positions 0
in BjH4/1D

˛j A

.nj C ˛j /A

@

Z

c
X

j D1

1

j D1

0

˛j A

j D1

0
@

0
ci
Y

@

j D1

.nj C

nj0

@

C ˛j /

.˛j /

j D1

0

c
X

@

˛j A
1:

.nj C nj0 C ˛j /A

j D1

We define an indicator vector I = [I1 ,    , Im ] to
indicate the hypothesis of different positions belong to,
where Ii = 1 means position i from H1, Ii = 2 means
position i from H2, Ii = 3 means position i from H3,
and Ii = 4 means position i from H4. Currently, we
are interested in the posterior distribution of I given the
data matrices A and B, i.e., P .IjA; B/. According to the
Bayes’ theorem, we have
P .I/P .A; BjA/
P .IjA; B/ D
:
X
P .I/P .A; BjI/
all possible I
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Therefore, we know that P .IjA; B/ / P .I/P .A;
BjI/. Based on the four hypotheses, we have
Y
P .A; BjI/ D
P .Ai ; Bi jIi /
Ii D1;2

P .dependent positions from H3/
P .dependent positions from H4/:
In our study, we assume in prior most positions
should be in H1 or H3 (i.e., unassociated with drug
resistance),
P .Ii D 1/ D P .Ii D 3/ D 0:98;
P .Ii D 2/ D P .Ii D 4/ D 0:01;
m
Q
P .I/ D
P .Ii /:
i D1

2.3

Metropolis-Hastings algorithm

Then we designed a Metropolis-Hastings (M-H)
algorithm (which is an algorithm for sampling from
probability distributions based on constructing a
Markov chain that has the desired distribution as its
equilibrium distribution) to sample from the posterior
distribution of I. 10 independent Markov chains are
stimulated with 20 000 iterations and the sampling starts
from the 5000th iteration. The procedure of M-H is as
follows:
(1) Initialize: randomly assign I a starting value I.t /
(t D 0).
(2) Propose: randomly choose one Ii.t / and change it
to other values with equal probabilities, the new
I is y.
(3) Evaluate: since the propose is symmetric,
so the acceptance probability is ˛.I.t / ; y/ D
minf1; P .I D yjA; B/=P .I D I.t / jA; B/g.
(4) Move: generate(u from Uniform(0,1) and set

y;
if u 6 ˛.I.t / ; y/I
I.t / ; otherwise.
(5) If t > N , stop; otherwise set t D t + 1 and
go to Step (2) (Here N is the total number of
iterations).
We applied BVP and RMS sequentially to the data
of treated and untreated patients. For the treated and
untreated comparison, we applied BVP to all treated
datasets (67 sequences) versus untreated dataset (457
sequences), and devised the difference between these
two, realizing that there exist different treated outcomes
that we should account for differently.
I .tC1/ =

3

Results

The structure of NS5A region is constituted by the
membrane attachment region (aa 1–236), the carboxyl
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region (aa 237–448). The carboxyl region consists of
PKRbd (aa 237–302), variable region 4 (V4; aa 310–
330), variable region 3 (V3; aa 381–409), the region
between V3 and V4 (aa 331–380), and V3 downstream
region (aa 410–448).
Our analysis is based on the four hypotheses we
mentioned above. Hypotheses 2 and 4 are most
probably for most of the mutating position and our
findings indeed verified this observation.
In order to study the mutation pattern differences
between treated and untreated individuals, we used
BVP and RMS to analyze the sequences from
treated (67 sequences) and untreated (457 sequences)
patients. Table 1 shows the results detailing the
positions that have high enough probabilities (95%
or more) for us to make inference regarding our
hypotheses. As we can see from Table 1, the
results from different Markov chains seem to vary,
possibly because of the noise from local modes,
where chains stuck. An interesting observation is that
among positions from about 380 to 400, there are no
differences between treated and untreated patients in
this region. A sample Markov chain from the 20 chains
we generated with different hypotheses distributions is
available in Fig. 1. This region is corresponding to V3
in NS5A. From this information, we could conclude
Table 1 Positions whose posterior probabilities of H2 or H4
are larger than 0.95.
Chain H2 (P>0.95)
H4 (P > 0:95/
1
null
56
2
null
343, 404
3
null
14, 101, 166, 313
4
null
160
5
null
null
6
null
160, 164
7
null
14, 24, 101, 166, 203, 313, 337
8
null
68, 161, 284, 444
9
null
68, 161, 444
10
null
78, 135, 296
11
null
null
12
null
78, 135, 296
13
null
227, 270, 279
14
null
175, 222, 270, 284, 381
15
null
14, 62, 166, 236, 313
16
null
23, 101, 131, 249, 295, 313, 385
17
null
260
18
null
14, 68, 101, 161, 166, 249, 257, 313, 384, 385
19
null
30, 56
20
null
270, 279, 284, 381

Table 2 Detailed position interaction relations for positions
78, 135, 296, 343, 404, 311, and 358.
488

Fig. 1 Hypotheses distribution (H1, H2, H3, and H4) in a
sample Markov Chain.

that IFN plus ribavirin therapy does not cause sequence
changes in V3.
Aside from the interesting finding above, Fig. 2 and
Table 2 show BVP-detected interacting positions and
RMS-inferred dependence structure. In positions 78,
135, and 296, we found that amino acid combination
KAI, which consisted 5.8% in the untreated sample,
disappeared in the treated sample. Similar decreases
were seen in some other combinations: RSI, KTL,
and RAV. It seems that interferon-based treatment is
very useful for the amino acids combinations mentioned
above. It is also worth noting that some significant
increase was observed. The combination KSV almost
tripled its part from 0.6% to 1.5% after treatment, the
combination KTI increased to 16.7% in the treated
samples compared to 13.2% in untreated ones, and the
combination RTV increased from 2.1% to 4.5%. Results
from positions 343 and 404 exhibit similar trends with
some combinations decrease in frequency significantly
while some increase in frequency after treatment.
We also looked at single positions significant under
Fisher test and noticed that even single positions
revealed treatment effects in terms of amino acid

Fig. 2 Flowchart of detected mutation positions and
position combinations.
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Positions 78,
135, 296
Amino acids
Percentage
Percentage
combinations (in
in untreated
in treated
order of 78, 135, 196)
sequences (%)
sequences (%)
KAV
19.9
22.7
KTI
13.2
16.7
KTV
6.1
4.5
RTI
48.5
47.0
RTV
2.1
4.5
RAI
2.1
3.0
KAI
5.8
0.0
RSI
0.3
0.0
KTL
0.3
0.0
RAV
0.6
0.0
RNI
0.3
0.0
KSV
0.6
1.5
Positions 343, 404
Amino acids
Percentage
Percentage
combinations (in
in untreated
in treated
order of 343, 404)
sequences (%)
sequences (%)
PC
83.4
80.3
AP
0.3
0.0
PG
0.3
0.0
AH
3.4
3.0
PR
6.1
7.6
PS
2.1
3.0
PP
0.6
1.5
AR
1.2
1.5
AC
0.9
1.5
PH
1.2
0.0
PL
0.3
0.0
PQ
0.0
1.5
Position 311 (Fisher test significant)
Percentage
Percentage
Amino acids
in untreated
in treated
sequences (%)
sequences (%)
P
61.3
66.7
Q
31.3
21.2
S
2.8
1.5
R
1.8
9.1
H
1.8
0.0
L
0.6
0.0
K
0.3
1.5
Position 358 (Fisher test significant)
Percentage
Percentage
Amino acids
in untreated
in treated
sequences (%)
sequences (%)
K
99.4
0.6
frequency. At position 311, the ratio of amino acid S
R
95.5
4.5
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decreased from 31.3% to 21.2% after treatment, and
so did amino acids H and L, both disappeared after
treatment. At position 358, the ratio of amino acid R
increased almost three folds from 0.6% to 4.5% after
treatment.

4

[4]

Discussion

Utilizing the innovative method proposed by Zhang et
al.[14] , which connected Bayesian statistical modeling
with molecular dynamic simulations, we were able to
investigate the complex interactions of drug resistance
mutations in HCV proteases and reverse transcriptase.
This paper, however, is admittedly a baseline analysis
of the treatment effects that ignores many other factors
that possibly affect HCV virus mutations. For instance,
different pre-treatment patterns are observed in patients
data, which may explain some of the inconsistency
exhibited in the result. Another issue lies in the
differences of treatment effects, which may also affect
the genome of sequence of HCV virus.
Despite all other possibilities may occur, this study
has demonstrated the original findings of HCV drug
resistance and showed a long puzzled selection pattern
of HCV drug treatment effects. All the methods and
results here will enlighten new and more accurate ways
to uncover some new finds behind HCV drug resistance
and other related diseases.

[5]
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